

May 14, 2009

Rheumatology Snapshot: Osteoarthritis



Event: Annual Congress of the European League Against Rheumatism,



Marketed Osteoarthritis Drugs

Pfizer (NYSE:PFE): Celebrex - Non-steroidal anti-inflammatory drug (NSAID): 2008 Sales USD 2,489m

- [Pfizer gets preliminary approval for settlement over Bextra and Celebrex](#)
- [Pfizer to resolve litigation involving its NSAID medication](#)
- [Pfizer lawsuit over Celebrex and Bextra can go forward](#)

Novartis (VTX: NOVN): Voltaren - Cyclooxygenase Inhibitors: 2008 Sales USD 814m

Pfizer (NYSE:PFE): Dynastat - Cox-2 Inhibitor: 2008 Sales USD 138m

Genzyme (NASDAQ:GENZ): Synvisc - Non-sulfated glycosaminoglycan: 2008 Sales USD 263m

- [Anika Therapeutics Monovisc will need head-to-head study with current standard of care in order to gain footing in the osteoarthritis market, physicians say \(Pharmawire\)](#)
- [Genzyme's new version of Synvisc works better than placebo](#)
- [Genzyme's Synvisc-One provides osteoarthritis patients with a one-shot injection, could capture larger market from improved patient compliance \(Pharmawire\)](#)

Anika Therapeutics (NASDAQ:ANIK): Monovisc - hyaluronic acid based therapy

- [Anika Therapeutics Monovisc will need head-to-head study with current standard of care in order to gain footing in the osteoarthritis market, physicians say \(Pharmawire\)](#)

Boehringer Ingelheim (Private): Mobic - Non-steroidal anti-inflammatory drug (NSAID)



Unpartnered Targets in Development

NicOx SA (EPA: COX): Naproxcinod - Cox-Inhibiting Nitric Oxide Donator (CINOD)

- [NicOx's naproxcinod Phase III data new results presented at ACC annual meeting](#)
- [NicOx's naproxcinod shows robust blood pressure results in Phase 3 pooled analysis](#)
- [NicOx's naproxcinod shows positive efficacy, safety and blood pressure results in third pivotal Phase 3 study](#)
- [Experts are confident upcoming data on naproxcinod will be positive; Company hopes for label which differentiates drug from competitors \(Pharmawire\)](#)
- [NiCox optimistic on naproxcinod data; unconcerned that only one efficacy study conducted against current standard of treatment \(Pharmawire\)](#)

SantoSolve AS (Private): 2PX - Topical Analgesics

- [SantoSolve in partnership talks over novel analgesic, takeover possible, CEO says \(Pharmawire\)](#)
- [SantoSolve reports positive Phase II results in patients with osteoarthritis](#)

Combinatorx (NASDAQ:CRXX): Synavive (CRx-102) - Dissociated steroid

- [UPDATE: CombinatoRx in active talks to partner arthritis drug Crx-102; deal could materialize 6-9 months following data release in October \(Pharmawire\)](#)
- [CombinatoRx: Crx-102 clinical study for rheumatoid arthritis should include two additional trial arms, physicians also want long-term data \(Pharmawire\)](#)
- [CombinatoRx completes enrollment of Phase IIb trial for CRx-102](#)
- [CombinatoRx's CRx-102 results of Phase 2a hand osteoarthritis trial warrants Phase 2b](#)

Neurotune AG (Private): NT-11624 - NMDAR antagonists

Merckle GmbH (Private): Licofelone - Dual COX/LOX inhibitor

Anesiva (NASDAQ: ANSV): Adlea - Long-acting non-opioid analgesic

A.P. Pharma (NASDAQ: APPA): APF505 - Non-steroidal anti-inflammatory drug (NSAID)

Biodelivery Sciences International (NASDAQ: BDSI): BEMA Buprenorphine - Partial mu-opiate receptor agonist